Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction Angiography（DSA）for pancreatic cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fuda Cancer Hospital, Guangzhou
NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more
NCT06160323 · Pancreatic Cancer Non-resectable, Tumor Pancreas, and more
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions